KR20220051365A - 타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체 - Google Patents

타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체 Download PDF

Info

Publication number
KR20220051365A
KR20220051365A KR1020227009059A KR20227009059A KR20220051365A KR 20220051365 A KR20220051365 A KR 20220051365A KR 1020227009059 A KR1020227009059 A KR 1020227009059A KR 20227009059 A KR20227009059 A KR 20227009059A KR 20220051365 A KR20220051365 A KR 20220051365A
Authority
KR
South Korea
Prior art keywords
methyl
indazol
dihydrothieno
cyclopenta
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227009059A
Other languages
English (en)
Korean (ko)
Inventor
샤오-정 펑
추-빈 리아오
헝-준 후앙
위안-팅 초
이-메이 창
우-치 판
Original Assignee
재단법인 생물기술개발중심
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 생물기술개발중심 filed Critical 재단법인 생물기술개발중심
Publication of KR20220051365A publication Critical patent/KR20220051365A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227009059A 2019-08-23 2020-08-22 타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체 Pending KR20220051365A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891097P 2019-08-23 2019-08-23
US62/891,097 2019-08-23
PCT/US2020/047552 WO2021041276A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20220051365A true KR20220051365A (ko) 2022-04-26

Family

ID=74685735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009059A Pending KR20220051365A (ko) 2019-08-23 2020-08-22 타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체

Country Status (11)

Country Link
US (1) US12448394B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017853A4 (cg-RX-API-DMAC7.html)
JP (1) JP7651557B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220051365A (cg-RX-API-DMAC7.html)
CN (1) CN114502553B (cg-RX-API-DMAC7.html)
AU (1) AU2020337883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151821A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002062A (cg-RX-API-DMAC7.html)
TW (1) TWI759829B (cg-RX-API-DMAC7.html)
WO (1) WO2021041276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278010A (zh) * 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
RU2425677C2 (ru) 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
BRPI0618011A2 (pt) * 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
WO2013142382A1 (en) * 2012-03-22 2013-09-26 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US8853207B2 (en) * 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN119792569A (zh) 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物

Also Published As

Publication number Publication date
CN114502553A (zh) 2022-05-13
AU2020337883B2 (en) 2025-08-28
WO2021041276A1 (en) 2021-03-04
EP4017853A4 (en) 2023-08-30
US12448394B2 (en) 2025-10-21
MX2022002062A (es) 2022-04-25
TWI759829B (zh) 2022-04-01
AU2020337883A1 (en) 2022-03-24
CN114502553B (zh) 2024-07-26
TW202115087A (zh) 2021-04-16
EP4017853A1 (en) 2022-06-29
CA3151821A1 (en) 2021-03-04
US20220289759A1 (en) 2022-09-15
JP7651557B2 (ja) 2025-03-26
BR112022003383A2 (pt) 2022-05-17
JP2022545019A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
CN107922431B (zh) Hpk1抑制剂及其使用方法
JP2021506864A (ja) Sos1阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
TWI648266B (zh) 作為第iii型受體酪胺酸激酶抑制劑之喹㗁啉化合物
TW202521536A (zh) Cdk抑制劑
JP2018502853A (ja) 炎症およびがんを処置するための複素環式itk阻害剤
JP2021514373A (ja) Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体
CN104812756A (zh) 多激酶通路抑制剂
KR20150027121A (ko) 신규 화합물
HUE030773T2 (en) Nitrogen-containing heterocyclic compounds with inhibitory effect on the production of quinurenine
KR20220085735A (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도
TW201604188A (zh) 雜芳族化合物及其作為多巴胺d1配體之用途
US20180072750A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
JP7651557B2 (ja) Iii型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体
CA2946990A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
WO2023008577A1 (ja) Ras/Raf結合阻害化合物
CN114555597A (zh) 异柠檬酸脱氢酶(idh)抑制剂
HK40012508A (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
HK40012508B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902